John A. Powelson

John A. Powelson

Auto-generated profile, based on publicly available information

John A. Powelson

Department of Surgery Indiana University School of Medicine Indianapolis Indiana USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2016 in American Journal of Nephrology
Verified
Journal Article
Open access
BEBurcin Ekser
Burcin Ekser
RMRichard S. Mangus
Richard S. Mangus
CKChandrashekhar A Kubal
Chandrashekhar A Kubal
JFJonathan A. Fridell
Jonathan A. Fridell
JPJohn A. Powelson
John A. Powelson
WGWilliam C. Goggins
William C. Goggins
Background: Enteric hyperoxaluria (EH) occurs with a rate of 5-24% in patients with inflammatory bowel disease, ileal resection and modern bariatric surgery. The excessive absorption of calcium oxalate causes chronic kidney disease (CKD) in patients with EH. In the literature, a single experience was reported in combined intestine-kidney transplantation (CIKTx) in patients with CKD due to EH. Methods: After a report of 2 successful cases of CIKTx in patients with EH and CKD, one was performed at our center in a 59-year-old Caucasian female who developed intestinal failure with total parenteral nutrition (TPN) dependence after a complication post-bariatric surgery. Before CIKTx, she underwent kidney transplantation alone (KTA) twice, which failed due to oxalate nephropathy. Results: In July 2014, the patient underwent CIKTx and bilateral allograft nephrectomy to avoid EH and oxalate stone burden. The postoperative course was complicated with acute tubular necrosis due to the use of high pressors related to perioperative bleeding. The patient was discharged 79 days after CIKTx with a serum creatinine (sCr) of 1.2 mg/dl and free of TPN. Her sCr increased at 7 months and a renal biopsy showed oxalate nephropathy. SLC26A6 (oxalate transporter) staining was significantly diminished in native duodenum/rectum as well as in intestinal allograft compared to control. Conclusions: KTA in patients with CKD secondary to EH should not be recommended due to high risk of recurrence. Although other centers showed good long-term outcomes in CIKTx, our patient experienced recurrence of EH due to oxalate transporter defect, early kidney allograft dysfunction and prolonged antibiotic use.

3 November 2023 in Clinical Transplantation
Verified
Journal Article
Open access
ADAllison M. Drury
Allison M. Drury
HAHashem N Albunni
Hashem N Albunni
MAMohammad Al-Haddad
Mohammad Al-Haddad
JPJohn A. Powelson
John A. Powelson
ALAndrew Lutz
Andrew Lutz
JFJonathan A. Fridell
Jonathan A. Fridell
Gastroparesis is a common complaint among patients with diabetes. Symptoms tend to improve following successful pancreas transplantation (PTx), but persist despite euglycemia in a subset of patients. We aimed to assess the benefit of gastric peroral endoscopic myotomy (G‐POEM) in persistent gastroparesis following PTx. This was a single center retrospective review of all patients who underwent G‐POEM for persistent gastroparesis following PTx. Patient demographics, pre and post procedure perception of symptom severity according to the patient assessment of upper gastrointestinal symptoms severity index (PAGI‐SYM), gastroparesis cardinal symptom index (GCSI) score, and 36‐item short form survey (SF36) score along with gastric emptying scintigraphy (GES) were analyzed. Seven PTx recipients underwent G‐POEM for persistent gastroparesis symptoms. The majority were female. All reported nausea/vomiting, abdominal pain, bloating, and post prandial fullness prior to G‐POEM. The post procedure survey scores improved in all patients although this was not significant. The improvement in gastric emptying on GES was statistically significant. G‐POEM is a relatively new treatment option for gastroparesis. While it requires specialized proceduralist and training, we have documented improvement in the management of symptoms. With increasing experience, we anticipate more significant benefit in post PTx patients with persistent symptoms of gastroparesis undergoing G‐POEM.

24 September 2025 in Clinical Transplantation
Verified
Journal Article
Open access
JCJeanne M. Chen
Jeanne M. Chen
RMRichard S. Mangus
Richard S. Mangus
ASAsif A. Sharfuddin
Asif A. Sharfuddin
JPJohn A. Powelson
John A. Powelson
MYMuhammad Sohail Yaqub
Muhammad Sohail Yaqub
JFJonathan A. Fridell
Jonathan A. Fridell
Belatacept may be used to spare or replace calcineurin inhibitors (CNI) to preserve renal function. Use in pancreas transplant (PTx) is limited by increased risk of pancreas rejection. This retrospective analysis included all PTxs performed between 2004 and 2023. A 1:2 case/control analysis was performed to identify predictors of belatacept use and compare allograft and patient survival. Of 731 PTxs, 21 (3%) started belatacept (eight simultaneous pancreas and kidney (SPK), three pancreas after kidney (PAK), and 10 pancreas transplant alone (PTA). At 1 year, Δ estimated glomerular filtration rate (eGFR) was +7% SPK, −15% PAK, and +32% PTA. Case–control analysis found no demographic predictors for belatacept except older recipient age for PTA. No difference in median kidney, pancreas, or patient survival was observed compared to control. Pancreas rejection occurred in two SPKs. There were two death censored pancreas allograft failures, both PTAs. Kidney allografts failed in two SPK and one PAK. Eight patients died. Six were still receiving belatacept at time of death with functioning allografts. Belatacept use after PTx is safe and can provide some renal recovery. Belatacept was initiated with eGFR approaching 20 mL/min/1.73m 2 . Earlier introduction may result in better outcomes.


9 April 2025 in Transplantation Direct
Verified
Journal Article
Open access
JFJonathan A. Fridell
Jonathan A. Fridell
JCJeanne M. Chen
Jeanne M. Chen
EKEmily A. Kerby
Emily A. Kerby
WMWilliam A. Marshall
William A. Marshall
ALAndrew J. Lutz
Andrew J. Lutz
RMRichard S. Mangus
Richard S. Mangus
Background.: Gastroparesis (GP) is a chronic disorder of the stomach characterized by delayed gastric emptying and frequently associated with longstanding diabetes. This is a single-center retrospective analysis designed to establish the prevalence and assess the impact on posttransplant outcomes of GP among pancreas transplant recipients. Methods.: Medical records for all recipients of pancreas transplants performed between January 2003 and December 2023 were reviewed. GP was defined by abnormal gastric-emptying scintigraphy or other motility study or a history of symptoms. Primary outcomes included graft loss and patient death. Clinical outcomes included length of stay after transplant and readmissions, including specifically for GP symptoms. Results.: Of 731 recipients, 156 (21%) were diagnosed with GP before transplant. Patients with GP were younger and more likely to be female individuals. Posttransplant, there was no difference in length of stay, graft survival, or patient survival. Patients with GP were more likely to be readmitted and to be specifically admitted for GP symptoms. Requirement for interventions was more common in patients with GP. Conclusions.: GP is identified with increased frequency among the specific patient population referred for pancreas transplant, and although it does not seem to affect allograft or patient survival, it does seem to have an impact on readmissions and the need for interventions.

26 April 2026 in Transplantation Proceedings
Verified
Journal Article
Closed access
PMP. Mihaylov
P. Mihaylov
CKChandrashekhar Kubal
Chandrashekhar Kubal
JFJ. Fridell
J. Fridell
JPJ. Powelson
J. Powelson